-- Adds Portfolio of Branded Products with $48.9 million in 2025 Net Sales and an Established Commercial Presence --

-- SYMPAZAN® Establishes a Neurology Rare Disease Footprint within Cosette --

-- Additional Brands include INDOCIN®, SPRIX®, ZIPSOR®, CAMBIA®, and OTREXUP® --

Cosette Pharmaceuticals, Inc., a U.S.-based, branded specialty pharmaceutical company, announced today the closing of a definitive agreement to acquire the U.S. sales and distribution rights for a portfolio of seven branded products from Assertio Holdings, Inc. (NASDAQ:ASRT). The acquisition expands Cosette's branded portfolio and adds the U.S. rights to SYMPAZAN®, a growing, patent-protected asset, further advancing Cosette's disciplined growth strategy.

SYMPAZAN® (clobazam) oral film is an FDA-approved medicine for the adjunctive treatment of seizures associated with Lennox‐Gastaut Syndrome (LGS), a rare and severe form of epilepsy, in patients 2 years of age or older. SYMPAZAN® is a growing product with patent protection extending until 2040. As the first and only FDA-approved oral film formulation of clobazam, SYMPAZAN® addresses an important unmet need for LGS patients and establishes a Neurology rare disease footprint within Cosette's branded portfolio.